{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-029405","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.307480+00:00","generated_at":"2026-06-18T10:35:02.620038+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvectis Pharma FY2022 net loss $19.1M; cash $20M; NXP800 Fast Track; NXP900 IND expected 1H23","bullets":["Cash and short-term investments $20.0M at Dec 31, 2022, up from $5.7M.","Net loss $19.1M vs $12.9M in 2021; R&D expense $13.2M; G&A $6.0M.","NXP800 granted Fast Track Designation for platinum-resistant, ARID1A-mutated ovarian cancer.","ENGOT and GOG Foundation to lead NXP800 Phase 1b trial in ovarian cancer.","NXP900 IND submission and Phase 1 start expected first half 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-029405","json":"https://secwatch.observer/filing/0001104659-23-029405.json","markdown":"https://secwatch.observer/filing/0001104659-23-029405.md","text":"https://secwatch.observer/filing/0001104659-23-029405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923029405/0001104659-23-029405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923029405/tm238641d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T10:35:02.620038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3aa977684ab7922570ea246ee43819555fd38c99","claim":"Nuvectis Pharma, Inc. reported the fiscal year ended December 31, 2022 results: net income $19.1 million.","evidence_excerpt":"Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923029405/0001104659-23-029405-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Net income","value":"$19.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}